KPV is the smallest fragment of the melanocortin system that retains a measurable biological effect: three amino acids — lysine, proline and valine — that sit at the very end of alpha-melanocyte-stimulating hormone (α-MSH). It is one of the better-characterised research tripeptides at the laboratory bench, and one of the least characterised in humans. This explainer sets out what the published record actually contains, and where the evidentiary gaps are.

01 — What KPV is

KPV has the sequence lysine–proline–valine (Lys-Pro-Val) and corresponds to residues 11–13 at the C-terminal end of α-MSH, a 13-amino-acid peptide derived from pro-opiomelanocortin (POMC). It is a small molecule: molecular weight ≈342.4 g/mol, formula C16H30N4O4 (PubChem CID 125672).

The reason researchers study the isolated tail rather than the full hormone is straightforward. Complete α-MSH drives melanocortin-receptor signalling in pigment cells — the basis of its tanning activity — alongside its anti-inflammatory effects. Isolating the three-residue C-terminus allows the anti-inflammatory activity to be studied separately from the pigmentary one. Much of the KPV literature rests on that separation.

KPV is not a marketed medicine in any jurisdiction, is not licensed by the MHRA, and has no approved human dose. It appears in the research-peptide supply chain as a "research use only" material.

02 — Mechanism: transport, then intracellular signalling

Two features distinguish KPV in the laboratory literature.

The first is how it enters cells. In intestinal models, KPV is taken up across the epithelium by PepT1, a di/tripeptide transporter whose expression rises in inflamed gut tissue. Because the peptide is only three residues long, this uptake does not depend on a classical cell-surface receptor — a property that has made KPV an unusually tractable tool for studying peptide transport in the gut.

The second is what it does once inside. Published cell and animal work describes inhibition of nuclear factor-κB (NF-κB), the transcription factor often described as a master switch for inflammatory gene expression. KPV is reported to stabilise the inhibitory protein IκBα — preventing the degradation that would otherwise free NF-κB — and to reduce nuclear translocation of the p65RelA subunit. Downstream, that is associated with lower expression of pro-inflammatory cytokines including TNF-α, IL-6 and IL-1β. Effects on MAP-kinase signalling have been reported in intestinal models and, more recently, in skin cells.

The receptor picture is not purely receptor-independent. In human bronchial epithelial cells, KPV activity has been linked to the MC3R melanocortin receptor as well as to intracellular signalling, so the mechanism is best described as context-dependent rather than as a single clean pathway. What is consistent across models is that KPV lacks the melanogenic activity of full-length α-MSH.

03 — The evidence base

The substantial KPV literature is preclinical — cell culture and animal models. The findings below are laboratory observations and should not be read as clinical outcomes.

Intestinal inflammation (animal models). The foundational study is Dalmasso et al. (2008, Gastroenterology), which showed that KPV is transported into colonic epithelial and immune cells via PepT1 and that oral KPV reduced disease severity and pro-inflammatory cytokine expression in dextran-sulfate-sodium (DSS) and TNBS mouse models of colitis. A companion study, Kannengiesser et al. (2008, Inflammatory Bowel Diseases), reported anti-inflammatory effects in a T-cell-mediated murine colitis model. A later Dalmasso study (2016, Cellular and Molecular Gastroenterology and Hepatology) examined PepT1 in colitis-associated cancer and reported therapeutic benefit from KPV in that murine model.

Delivery research. Xiao et al. (2017, Molecular Therapy) packaged oral KPV in hyaluronic-acid-functionalised nanoparticles and reported improved colonic delivery and efficacy versus free peptide in a colitis model. This is formulation science: it demonstrates that the peptide can be targeted to gut tissue in animals, not that it works in people.

Airway and skin models. Land (2012) studied KPV in human bronchial epithelial cells and proposed a role for MC3R signalling. Sung et al. (2025, Tissue & Cell) exposed human HaCaT keratinocytes to fine particulate matter and reported that KPV modulated oxidative stress and MAPK/NF-κB signalling. Human-derived cell lines make these studies more relevant than animal tissue, but they remain in-vitro experiments — not human trials.

04 — What the record does not contain

There is no published randomised controlled human trial of KPV for any indication. There is no established human pharmacokinetic dataset, no standardised safety profile in people, and no approved dosing. Statements about KPV's "anti-inflammatory benefits" in humans are extrapolations from cell and animal work, and the history of peptide research shows that such extrapolations frequently fail — the same step from promising preclinical signal to negative human endpoint recurs across this literature.

A common misreading is to treat a study in human cells as human evidence. A keratinocyte or bronchial-epithelial experiment establishes that a mechanism exists in a human cell type under laboratory conditions. It does not establish absorption, distribution, effective exposure, or clinical effect in a person. The distinction matters when reading vendor or forum summaries of the papers cited above.

05 — UK regulatory position

KPV is not a licensed medicine in the UK and is not a controlled drug under the Misuse of Drugs Act 1971. It occupies the grey area that applies to most research peptides: it may lawfully be supplied for bona fide research, but the MHRA has not authorised it for human use, and there is no UK product licence.

Two boundaries matter under UK law. First, the Human Medicines Regulations 2012 restrict the making of medicinal claims for an unlicensed substance — describing KPV as a treatment for colitis or any other condition would cross that line, which is why this article describes published research findings rather than therapeutic effects. Second, anything supplied for research use is supplied on that basis; the familiar "research use only" label is a statement of legal purpose, not a formality.

06 — How to read KPV research claims

  • Check the model. Every substantive finding above comes from mice, cell lines, or ex-vivo skin. None is a human trial.
  • Check the species of the cells. "Human keratinocytes" is still a dish experiment, not a person.
  • Check the endpoint. Reduced cytokine expression in a cultured cell line is a mechanistic result, not a clinical one.
  • Check the framework. Any UK-facing summary that implies KPV treats a condition, or offers dosing for human use, is outside both the evidence and the law.

On Peptide Data's four-tier grading, KPV carries a Limited evidence grade — a deep and internally consistent preclinical literature, but no human data. That is a genuine research signal, and it is not a clinical one.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.